

Our Ref: DC/NB

8th October 2025

To: Prescribing Clinicians and Pharmacists within the Barnsley locality

Dear Colleague

Re: Summary of Key Points from the Barnsley Area Prescribing Committee Meeting on 10th September 2025.

The main outcomes of the meeting were: -

Barnsley Prescribing Guidelines

The following Barnsley prescribing guideline will be stepped down and removed from the South Yorkshire Medicines Optimisation (SY MO) website:

- **Calcium and Vitamin D, and Vitamin D Summary of formulary choices in adults over 18 years** (information regarding formulary choices can be found in the [Vitamin D section](#) of the Barnsley Formulary and in the South Yorkshire Vitamin D Management in Adults Guidelines which can be accessed via the following pre-populated search on the SY MO website:
<https://mot.southyorkshire.icb.nhs.uk/search?locations=south-yorkshire%2Cbarnsley&q=vitamin+D&categories=Guideline>)

South Yorkshire Integrated Medicines Optimisation Committee (IMOC) approved Prescribing Guidelines

The following South Yorkshire IMOC approved position statement and prescribing guidelines were received by the Committee:

- **Prescribing of Medicines for the treatment of Dental Conditions on FP10 SY ICB Position Statement [NEW]**
This notes that the routine prescribing of medicines or preparations for dental conditions by GP practice based primary care prescribers (GPs/Non-Medical Prescribers) on FP10 is not supported by the SYICB.

GP practices should review and where appropriate discontinue the prescribing of medicines or preparations for dental conditions (e.g. fluoride toothpastes and mouthwashes, mouth ulcer healing preparations, analgesics and antibiotics), and recommend patients purchase these over the counter as self-care, or visit their dentist for advice and prescribing as appropriate. There are exceptions when the prescribing of medicines or preparations for dental conditions by GP practice based primary care prescribers may be appropriate and further information regarding these exceptions can be found within the position statement.

The position statement can be accessed via the following pre-populated search on the SY MO website: <https://mot.southyorkshire.icb.nhs.uk/search?locations=south-yorkshire%2Csouth-yorkshire%2Cbarnsley&categories=Guideline&q=dental>

- **South Yorkshire Guideline Lipid Modification (for the primary prevention of CVD) in younger Adults (18-39) with Type 2 Diabetes [NEW]**

This is intended to be used alongside existing lipid modification guidelines. The guideline can be accessed via the following pre-populated search on the SY MO website:

<https://mot.southyorkshire.icb.nhs.uk/search?locations=south-yorkshire%2Csouth-yorkshire%2Cbarnsley&categories=Guideline&q=lipid+modification>

- **South Yorkshire Children and Young People's Asthma Guideline 2025 [NEW]**

This new guideline, along with the existing Barnsley adult asthma guideline, can be accessed via the following pre-populated search on the SY MO website:

<https://mot.southyorkshire.icb.nhs.uk/search?locations=south-yorkshire%2Csouth-yorkshire%2Cbarnsley&categories=Guideline&q=asthma>

The SY Children and Young People's Asthma Guideline supersedes the children and young peoples's elements (0-17 years) of the Barnsley Asthma Guideline and this information has been added to the front page of the Barnsley Asthma Guideline.

South Yorkshire Integrated Medicines Optimisation Committee (IMOC) approved Amber G / Shared Care Guidelines

The following South Yorkshire IMOC approved shared care guideline was received by the Committee:

- **Shared Care protocol (SCP) for Sublingual Immunotherapy (SLIT) (Grazax®) / Acarizax®) - For adults and children diagnosed with severe allergic rhinitis to grass pollen or house dust mite [UPDATED]**

This guideline has received a minor update to incorporate [NICE TA1045](#). The shared care guideline can be accessed via the following pre-populated search on the SY MO website:

<https://mot.southyorkshire.icb.nhs.uk/search?locations=south-yorkshire%2Cbarnsley&q=immunotherapy&categories=Shared+Care>

Other

Accessing Prescribing Guidelines / Medicines Optimisation Resources

South Yorkshire wide and Barnsley place (together with Doncaster, Rotherham and Sheffield place) prescribing guidelines, shared care and amber G guidelines can be accessed via the central South Yorkshire ICB Medicines Optimisation website:

<https://mot.southyorkshire.icb.nhs.uk/> (home page)

or

<https://mot.southyorkshire.icb.nhs.uk/search?locations=barnsley%2Csouth-yorkshire> (Barnsley section which is pre-populated to search for Barnsley place or South Yorkshire wide prescribing and clinical guidelines and other medicines optimisation related information).

Guidelines can be located using the search function with the additional option of adding a corresponding category filter (e.g. shared care) if preferred.

Guidelines and other prescribing information can also be accessed via the Barnsley Joint Formulary: <http://www.barnsleyformulary.nhs.uk/>

Work continues to progress to replace existing links to local guidelines within the formulary and ScriptSwitch with links to the central SYMO website.

Healthcare professionals (including primary and secondary care clinicians and community pharmacists) are encouraged to report any medicines related interface issues (examples include shared care, prescribing guideline, formulary or discharge related issues), particularly where guidelines are not being complied with, to the following email address: BarnsleyAPCReport@nhs.net.

Barnsley Formulary Updates

The Committee noted the traffic light classifications recently assigned by the South Yorkshire Integrated Medicines Optimisation Committee (IMOC) and the following formulary positions were agreed by the Committee:

Drug	Indication	Barnsley Formulary status (including traffic light classification)
Horizon Scanning September 2025 IMOC		
Zolpidem (new orodispersible tablet formulation)	Short-term treatment of insomnia in adults in situations where the insomnia is debilitating or is causing severe distress for the patient	Zolpidem (chemical substance level) currently has a green classification. The formulary will be updated to note that zolpidem orodispersible tablet formulation has a significantly higher cost than the standard zolpidem generic tablets and should be reserved for use when the standard tablets are not considered appropriate.
Liothyronine (new oral solution formulation 10 micrograms/ml)	Use in adults and children for the treatment of coma of myxoedema, the management of severe chronic thyroid deficiency and hypothyroid states occurring in the treatment of thyrotoxicosis, and for the treatment of thyrotoxicosis as an adjunct to carbimazole to prevent sub-clinical hypothyroidism developing during treatment	Liothyronine (chemical substance level) has a formulary amber (shared care) classification. The new licensed oral solution formulation has a lower acquisition cost than the capsules and tablets.
Sildenafil citrate (new oromucosal spray formulation)	Use in adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance	Sildenafil (chemical substance level) currently has a green classification. The formulary has been updated to note that sildenafil oromucosal spray formulation has a significantly higher cost than the standard sildenafil generic tablets.
Other		
Dapagliflozin	Type 2 diabetes Chronic Kidney Disease Chronic Heart Failure with reduced Ejection Fraction (HFrEF) and Chronic Heart Failure with preserved or mildly reduced ejection fraction	The formulary is in the process of being updated to note that following the launch of generic formulations, dapagliflozin now has a lower acquisition cost than other SGLT2 inhibitors and should be considered as a first line option when an SGLT2 inhibitor is indicated.

		<p>No changes have been made to the existing traffic light classifications: Formulary green for use in Type 2 Diabetes / Chronic Kidney Disease.</p> <p>Formulary Amber-G for Chronic Heart Failure</p>
--	--	---

MHRA Safety Roundup

The August 2025 MHRA Drug Safety Roundup can be accessed at the following link:
https://assets.publishing.service.gov.uk/media/68b04e94f31f3b16cee0e90e/August_Safety_Roundup.pdf

There were no issues relating to primary care.

Kind Regards



Deborah Cooke
Senior Pharmacist [Strategy and Delivery - Barnsley & Clinical Effectiveness]

cc: Medicines Optimisation Team (Barnsley Place)
Rebecca Hoskins, BHNFT
Nisha Pounj-Taylor, BHNFT
David Bryant, BHNFT
Sarah Hudson, SWYPFT
Area Prescribing Committee Members (Secretary to the APC to circulate)
Local Medical Committee (Secretary to the LMC to circulate)
Heidi Taylor, South Yorkshire ICB
Ashley Hill, South Yorkshire ICB (IMOC Secretary)